Clinical Trial Update: Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias [Phase 2]

View source ↗

Summary

An extension study of fostamatinib (Syk inhibitor) for posttransplant immune-mediated cytopenias has been withdrawn, including autoimmune hemolytic anemia, immu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Graft-versus-host Disease
• Immune Thrombocytopenia

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Status: WITHDRAWN